Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by BearDownAZon Jan 15, 2019 11:22am
191 Views
Post# 29233536

BETonMACE ClinicalTrials.gov Updated

BETonMACE ClinicalTrials.gov Updated

Well, the last item of the "Waiting Game" list can now be checked off. BETonMACE ClinicalTrials.gov is now updated to "Active, not recruiting." Actual enrollment 2425 patients. The estimated primary completion date and estimated study completion date are both now listed as June 2019. I didn't notice any other changes at first glance.

https://clinicaltrials.gov/ct2/show/NCT02586155

I am unsure how to interpret that June 2019 date. My guess is that in all current correspondence (MD&A, conference presentations, new releases, trial listings, analyst reports) that Resverlogix is using/communicating H1 2019 (by June 2019) as a conservative/generic estimate for all anticipated trial timeline events. End of dosing may still come any day now; however, as discussed previously the adjudication and follow up process will take some time.

The next 6 months are sure to be interesting!

BearDownAZ

Bullboard Posts